• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The yield of urokinase produced by cell culture of kidney cells is improved by incorporating in the cell culture medium an elevated level of phenylalanine.
    公开号:SU927126A3
    申请号:SU792767757
    申请日:1979-05-23
    公开日:1982-05-07
    发明作者:Мау-Юнг-Куо；Джин Ринтс Маргрет；Фидер Джозеф
    申请人:Монсанто Компани(Фирма)；
    IPC主号:
    专利说明:

    (5) METHOD FOR OBTAINING UROKINASE
    I
    This invention relates to the chemical and pharmaceutical industry and relates to the manufacture of drugs.
    A method of producing urokinase is known by cultivating a culture of renal tissue in a liquid nutrient medium in the presence of an amino acid, followed by isolating the desired product 1.
    However, the known method does not provide a high yield of the target product.
    The purpose of the invention is to increase the yield of urokinase.
    This goal is achieved by the fact that when carrying out the method of obtaining urokinase by cultivating a culture of renal tissue in a liquid nutrient medium in the presence of an amino acid, followed by isolation of the target product, the cultivation is carried out in the presence of 0.3-0.5% phenylalanine.
    The method is carried out as follows.
    The kidney cells are grown in an appropriate nutrient medium in tissue culture vessels at up to cell fusion. Wednesday 199 is
    g typical, suitable growth medium. You can also use DuEbeceo EagEe Modified Medium, McCoy Medium 5A, Waymouth Medium MB 752/1, and other amphibious media
    IQ for tissue cultures. During growth, the culture medium is strengthened with mammalian serum, such as bovine fetal serum, in an amount of 5-15% by volume.
    Wednesday 15
    After the cell fusion, they are washed with a physiological solution, for example, a buffer brine, and then the washing liquid is replaced with a preservative.
    You can use the aqueous nutrient medium, which is necessary to preserve renal cells and to obtain urokinase. This
    25 Wednesday Soderhhit protein hydrolyzate molo392 ka, human serum albumin, glucose and sodium bicarbonate. In addition to milk protein hydrolyzate, other protein hydrolysates can also be used, such as tryptol, tryptose, peptone and other materials. PRI me R 1. Normal primary kidney cells of a human embryo (PCE) are centrifuged and resuspended in medium 199f containing 10% by volume of bovine embryo serum. The cell suspension is used to inoculate a reservoir of Falcon mass flasks with a capacity of 75 cm / 2, containing the same medium in quantities sufficient for the final culture to be 15-2 J3 ml, and the cell density is 1, OCh of cells per ml. The flasks are incubated at 37 ° C in an incubator containing S% Sop in the air. The medium in the flasks is changed every 2-3 days until the cultures merge. The cells in each flask are then washed with 25 ml of sterile, physiologically normal saline. After removing the washing solution, 10 ml of preservative agent contain 13.65 g / l of lactalbumin hydrolyzate medium; 2.2 g / l NaHCO, 0.1 weight. human serum albumin; (1.1 wt. D-glucose and 0.5 wt.% Phenylalanine. A sample is taken from the preservative for urokinase titers and replenished daily with 10 ml of the same fresh preservative. After four days of cultivation, the medium is removed and the cells are each flask is washed several times with 25 ml of brine and then with 1N NaOH solution. The analysis shows that the content of LH in the kidney cells of a human embryo is 9 µg of DNA (10 eclets). The analysis of urokinase is performed by a two-step method using iodine fibrin p In the first stage, urokinase acts on plasminogen to form plasmin. In the second stage, plasmin hydrolyzes the radiolabeled condensed fibrinogen (fibrin) to release fibrinoppeptide into the solution, measured with a gamma counter. are used as the amount of enzyme that hydrolyzes one mg of fibrin per hour. PRI im e P2. Normal primary kidney cells of a human embryo are cultured before confluence in T-75 flasks as described in Example 1, are also washed in a sterile saline solution and 90 ml of preservative are removed, phenylalanine is added to each flask. The medium is replenished with fresh medium, which is added to a 30 ml flask every three days. After nine days of cultivation in phenylalanine, the medium is removed, the cells are washed several times and the DNA content and urokinase titers are determined as in Example 1. In this example, the preservative consists of 13.75 g / l of lactalbumin hydrolyzate, 2.2 g / l NaHCO2 0.1 weight. D-Tlyukbzy. The amino acid and / or human serum albumin (HSA) is added to the main preservative to obtain the desired final concentration (% by weight). Analogously to Example 1, urokinase activity is determined in ml per day and µg of DNA. Comparative, data on the release of urokinase are presented in the table.
    No additive
    0, U HSA
    0.1 HSA + 0.3 glycine
    0, U HSA 0.5% glycine
    The final DNA content of the cells in each flask after nine days of cultivation in the preservative substance.
    The yield of urokinase obtained by culture in a liquid nutrient medium in
    stimulation of kidney cells in the presence of an amino acid, followed by the use of increased amounts of fecal secretion of the target product,
    nilalanine in a preservative substance, characterized in that
    This is generally higher than when used to increase urokinase yield,
    using other amino acids, gly cultivation is carried out in the presence of
    tsina, methionine, histidine. This is a superior-ZO0.3-0.5 0enilal “4na. Sustainability is also achieved when the number of cells (i.e., the DNA content) in the Sources of Information,
    lower taken into account in the examination
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining urokinase by E51- US Patent If EZZOE
    culture of renal culture. .7 publish 1976.
    Table continuation
    类似技术:
    公开号 | 公开日 | 专利标题
    SU927126A3|1982-05-07|Process for producing urokinase
    Barbour1984|Isolation and cultivation of Lyme disease spirochetes.
    Bowman et al.1982|Primary culture of microvascular endothelial cells from bovine retina
    US4352887A|1982-10-05|Method and article for culturing differentiated cells
    US6306644B1|2001-10-23|Device for cultivating different mammal cells at the same time
    CA1093995A|1981-01-20|Rapid propagation of sv3t3 cells for production of mif and taf
    CN107058219A|2017-08-18|A kind of method that application stem cell self-characteristic prepares dental pulp stem cell
    SE432778B|1984-04-16|WAY TO ADAPT NORMALLY ANCHORING DEPENDENT ESTABLISHED CELL LINES TO SUSPENSION CULTURE
    Gilbert et al.1977|Renal enzymes in kidney cells selected by D‐valine medium
    CN107557331A|2018-01-09|A kind of method for separating and cultivating human adipose-derived stem cell
    JP4233646B2|2009-03-04|Method for increasing the stability and / or shelf life of various substrates
    DK175366B1|2004-09-13|Process for Preparation of Biologically Active Human Tissue Type Plasminogen Activator
    US4501815A|1985-02-26|Article for culturing differentiated cells
    CN102517251A|2012-06-27|Mesenchymal stem cells, as well as preparation method and application thereof
    Keller et al.1974|Induction of creatine phosphokinase in cultures of chick skeletal myoblasts without concomitant cell fusion
    CA1054085A|1979-05-08|Urokinase production
    US4169761A|1979-10-02|Process for the cultivation of viruses
    GILIN et al.1980|Attachment and short‐term maintenance of motility and viability of Entamoeba histolytica in a defined medium
    CN109295136A|2019-02-01|A method of large-scale production fetal stem cell secretin
    CN107287158A|2017-10-24|The method of effective acquisition mescenchymal stem cell from mouse dense bone
    Chan et al.1973|Culture of erythropoietic cells from chick blastoderms
    Baker et al.1939|ARTIFICIAL MAINTENANCE MEDIA FOR CELL AND ORGAN CULTIVATION: I. THE CULTIVATION OF FIBROBLASTS IN ARTIFICIAL AND SERUMLESS MEDIA
    US3930944A|1976-01-06|Urokinase production
    RU2039816C1|1995-07-20|Preparation for detaching contact-dependent cells from substrate
    CN109430251A|2019-03-08|A kind of store method of the preservation liquid of adipose tissue and preparation method thereof with adipose tissue
    同族专利:
    公开号 | 公开日
    EP0005644A2|1979-11-28|
    MX5901E|1984-08-22|
    HU179549B|1982-11-29|
    JPS629319B2|1987-02-27|
    CA1114761A|1981-12-22|
    AU522609B2|1982-06-17|
    DK152138B|1988-02-01|
    DE2965182D1|1983-05-19|
    DK152138C|1988-08-08|
    US4190708A|1980-02-26|
    DK212079A|1979-11-25|
    AU4734379A|1979-11-29|
    EP0005644A3|1979-12-12|
    EP0005644B1|1983-04-13|
    JPS54163887A|1979-12-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2930945A|1956-08-16|1960-03-29|Vickers Inc|Power transmission|
    US3904480A|1972-10-24|1975-09-09|Lilly Co Eli|Enhanced production of plasminogen activator|
    US3930944A|1975-03-31|1976-01-06|Abbott Laboratories|Urokinase production|
    AR208001A1|1975-03-31|1976-11-22|Abbott Lab|IMPROVED PROCEDURE FOR THE PRODUCTION OF UROQUINASE|NL8003402A|1980-06-11|1982-01-04|Leuven Res & Dev Vzw|NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION.|
    JPS5852634B2|1980-12-05|1983-11-24|Hayashibara Seibutsu Kagaku Kenkyusho Kk|
    US4659655A|1981-11-25|1987-04-21|Bio-Response, Inc.|Method for isolating product-producing cells|
    US5112755A|1982-04-15|1992-05-12|Genentech, Inc.|Preparation of functional human urokinase proteins|
    FI831484L|1982-05-05|1983-11-06|Genentech Inc|PLASMINOGEN AKTIVATOR FOER MAENSKOVAEVNAD|
    MX197183A|1982-05-05|1994-02-28|Genentech Inc|HUMAN TISSUE PLASMINOGEN ACTIVATOR|
    US5185259A|1982-05-05|1993-02-09|Genentech, Inc.|Truncated human tissue plasminogen activator|
    US4766075A|1982-07-14|1988-08-23|Genentech, Inc.|Human tissue plasminogen activator|
    US4853330A|1983-04-07|1989-08-01|Genentech, Inc.|Human tissue plasminogen activator|
    US5011795A|1983-01-19|1991-04-30|Genentech, Inc.|Human tPA production using vectors coding for DHFR protein|
    US4550080A|1984-06-05|1985-10-29|Asahi Kasei Kogyo Kabushiki Kaisha|Process for the preparation of a plasminogen activator|
    US4851517A|1986-02-26|1989-07-25|Monsanto Company|Tissue plasminogen activator oligosaccharide from normal human colon cells|
    US4927630A|1986-02-26|1990-05-22|Monsanto Company|Tissue plasminogen activator from normal human colon cells|
    US4751084A|1986-02-26|1988-06-14|Monsanto Company|Tissue plasminogen activator from normal human colon cells|
    US5132214A|1986-04-09|1992-07-21|Monsanto Company|Large scale production of plasminogen activator from normal human colon cells|
    US4920051A|1988-02-03|1990-04-24|Damon Biotech, Inc.|Recovery of urokinase compounds|
    JP2548915Y2|1991-04-02|1997-09-24|カヤバ工業株式会社|Heavy load support device|
    CN110607272A|2019-09-23|2019-12-24|山东甲骨文生物科技有限公司|Additive of mammalian cell culture solution and cell culture solution|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/909,137|US4190708A|1978-05-24|1978-05-24|Production of urokinase|
    [返回顶部]